ReviewNeuroscience applied2026
Old enough to be a model? On the role of maturity in stem cell-based models for neuropsychiatric disorders.
Review in Neuroscience applied, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mental disorders profoundly influence cognition, emotion, and self-perception, and collectively represent a major cause of global disability. Their onset spans distinct developmental periods, from early childhood in neurodevelopmental conditions such as autism spectrum disorder, through adolescence in eating and obsessive-compulsive disorders, to early adulthood in bipolar disorder and schizophrenia. Twin and family studies have established that these disorders are substantially heritable, and large-scale genomic analyses have identified numerous common and rare risk variants. Yet, the biological mechanisms through which genetic and environmental factors converge to shape disease trajectories remain elusive. Patient-derived induced pluripotent stem cells (iPSCs) have emerged as a promising tool for investigating disease-relevant mechanisms in human neurons and neural circuits. However, most iPSC-derived neural cells and organoids resemble embryonic/fetal-stage brain tissue in both molecular and functional characteristics, raising questions about their relevance for disorders that manifest later in life. In this narrative review, we discuss how developmental timing, both in disease onset and in cellular models, shapes the interpretation of iPSC-based findings. We outline how differences in neuronal maturity may constrain or enable mechanistic insight, summarize emerging methods for accelerating or extending neuronal aging
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.